Market Watch
05 Aug 2026, 11:04 UTC · 2h ago
Lilly's revenue soars 48%, driven by demand of its GLP-1s
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Market Watch
05 Aug 2026, 11:04 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Sales were driven by higher-than-expected demand for GLP-1 drugs Mounjaro and Zepbound. — Stronger-than-anticipated demand for high-growth blockbuster drugs typically drives significant stock price appreciation and revenue revisions.
+0.80Which stocks this story touches
Higher-than-expected demand for its key drugs Mounjaro and Zepbound is driving sales growth.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
36m ago
